Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer.
To investigate the best first-line chemotherapy regimen for the treatment of advanced epithelial ovarian cancer (AEOC), the efficacy of three chemotherapy regimens for treatment of the patients with AEOC in our hospital during Jan. 1992-Jan. 1999 was retrospectively analyzed. The therapeutic effects were compared with the supplement of Melphalan + Hexamethylme (PAM + HMM), cisplatin + adriamycin + cyclophosphamide or isofamide (PAC) or cisplatin + cyclophosphamide or isofamide (PC), Taxol + cisplatin (TP) combined chemotherapy after cytoreductive surgery. The results showed that the overall effective rate of TP was significantly higher than that of PAM + HMM (P < 0.05); The complete remission rate of TP was significantly higher than that of PAM + HMM and PAC or PC (all P < 0.05); The 2-year survival rate free of tumor of TP was obviously higher than that of PAM + HMM and PAC or PC (all P < 0.05). It was concluded that the therapeutic effect of TP regimen in the treatment of AEOC was better than PAM + HMM and PAC or PC and TP regimen could be recommended currently as the preferred first-line one for the treatment of AEOC.
Wang
C
C
Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical University, Wuhan 430030.
Gu
M
M
Wang
S
S
Ma
D
D
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D006585:Altretamine / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018282:Cystadenocarcinoma, Mucinous / Q000188:drug therapy; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy*; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D017239:Paclitaxel; D012189:Retrospective Studies; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D016896:Treatment Outcome
D043823:Taxoids; D016685:Mitomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D017239:Paclitaxel; D002945:Cisplatin; D006585:Altretamine